Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
This method uses radiation to break up the affected cells, helping patients avoid surgery while still delivering effective treatment
Our Media Release in response to the TGA Final Decision Breaking News: The TGA Announces the Delegates Final Decision to Reschedule the Use of Psilocybin and MDMA for Medical Purposes Read our media release here - 3 February 2023 The TGAs Interim Decisions against Rescheduling The TGAs Interim Decisions against Rescheduling The TGA Announced its Interim Decisions against Rescheduling on 21 October 2022
The clinic provides exceptional care, state-of-the-art treatments, and outstanding customer service
